A
Adriel C. Cha
Researcher at Stanford University
Publications - 5
Citations - 2497
Adriel C. Cha is an academic researcher from Stanford University. The author has contributed to research in topics: Antigen & Cancer. The author has an hindex of 4, co-authored 5 publications receiving 1940 citations.
Papers
More filters
Journal ArticleDOI
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham,Jens Peter Volkmer,Andrew J. Gentles,Debashis Sahoo,Piero Dalerba,Siddhartha Mitra,Jian Wang,Humberto Contreras-Trujillo,Robin Martin,Justin D. Cohen,Patricia Lovelace,Ferenc A. Scheeren,Mark P. Chao,Kipp Weiskopf,Chad Tang,Anne Kathrin Volkmer,Tejaswitha J. Naik,Theresa A. Storm,Adriane Mosley,Badreddin Edris,Seraina Schmid,Chris K. Sun,Mei-Sze Chua,Oihana Murillo,Pradeep S. Rajendran,Adriel C. Cha,Robert K. Chin,Dongkyoon Kim,Maddalena Adorno,Tal Raveh,Diane Tseng,Siddhartha Jaiswal,Per Øyvind Enger,Gary K. Steinberg,Gordon Li,Samuel So,Ravindra Majeti,Griffith R. Harsh,Matt De Van Rijn,Nelson N.H. Teng,John B. Sunwoo,Ash A. Alizadeh,Michael F. Clarke,Irving L. Weissman +43 more
TL;DR: All human solid tumor cells require CD47 expression to suppress phagocytic innate immune surveillance and elimination, showing that CD47 is a commonly expressed molecule on all cancers, its function to blockphagocytosis is known, and blockade of its function leads to tumor cell phagcytosis and elimination.
Journal ArticleDOI
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao,Ash A. Alizadeh,Chad Tang,June Helen Myklebust,June Helen Myklebust,Bindu Varghese,Saar Gill,Max Jan,Adriel C. Cha,Charles Chan,Brent T. Tan,Christopher Y. Park,Feifei Zhao,Holbrook E Kohrt,Raquel Malumbres,Javier Briones,Randy D. Gascoyne,Izidore S. Lossos,Ronald Levy,Irving L. Weissman,Ravindra Majeti +20 more
TL;DR: The eradication of human NHL solely with a monoclonal antibody therapy combining rituximab with a blocking anti-CD47 antibody, which synergized through a mechanism combining Fc receptor (FcR)-dependent and FcR-independent stimulation of phagocytosis that might be applicable to many other cancers.
Journal ArticleDOI
Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker
Max Jan,Mark P. Chao,Adriel C. Cha,Ash A. Alizadeh,Andrew J. Gentles,Irving L. Weissman,Ravindra Majeti +6 more
TL;DR: In this article, the identification of TIM3 as an AML stem cell surface marker more highly expressed on multiple specimens of acute myeloid leukemia (AML) LSC than on normal bone marrow HSC was reported.
Journal ArticleDOI
Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 “Don't Eat Me” Signals
TL;DR: Agents that block the CD47:SIRP-α engagement are attractive therapeutic targets as a monotherapy or in combination with additional immune-modulating agents for activating antitumor T cells in vivo.
Proceedings ArticleDOI
Abstract PR13: The anti-CD47 antibody Hu5F9-G4 is a novel immune checkpoint inhibitor with synergistic efficacy in combination with clinically active cancer targeting antibodies
Mark P. Chao,Mckenna Kelly Marie,Adriel C. Cha,Dongdong Feng,Jie Liu,Branimir I. Sikic,Ravindra Majeti,Irving L. Weissman,Chris H. Takimoto,Jens-Peter Volkmer +9 more
TL;DR: The combination of Hu5F9-G4 with anti-EGFR mAbs can rescue efficacy of EGFR mAb activity in RAS mutant CRC and that synergistic efficacy is independent of mutations in intrinsic tumor signaling pathways and resistance.